Valuation dashboard for Syndax Pharmaceuticals, Inc. (SNDX) with P/E N/A, P/B 101.04, EV/EBITDA -14.93 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML).
Analysis Summary
Syndax Pharmaceuticals, Inc. reported revenue of $172.4M in the most recent fiscal year, growing at a 5-year CAGR of 157.7%.
Trailing-twelve-month margins: gross margin 97.5%, operating margin -77.1%, net margin -87.6%.
At the current price of $17.28, SNDX has negative trailing earnings (P/E not meaningful) and an ROE of -372.94%. Market capitalisation stands at $1.5B.
Balance sheet quality for SNDX: current ratio of 4.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 101.04 |
| EV / EBITDA | -14.93 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $13.47 |
| vs Current Price | -22.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals, Inc. | $1.5B | 101.04 | -372.9% | |
| RLAY | Relay Therapeutics, Inc. | $4.1B | 4.29 | -48.8% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.6B | |||
| ATAI | Atai Beckley Inc. | $2.7B | 10.53 | -366.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
Price
| Price | $17.28 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -372.94% |
| Return on Invested Capital | -32.10% |
| Return on Assets | -31.37% |
| Gross Margin | 97.47% |
| Operating Margin | -77.05% |
| Net Margin | -87.60% |
Related companies: AMLX · ATAI · CVAC · IMTX · INBX · NKTR · ORIC
Explore sector: Healthcare · Biotechnology
More sections of SNDX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks